On September 12, Baiyang Intelligent Technology Co., Ltd. and Bairui Gene Group signed a cooperation agreement in Beijing. Both parties will use their respective resources to effectively promote the landing of Watson for Genomics (Watson Gene Solutions, WfG) in China. Development, along with the achievement of cooperation between the two parties, marks the first time that the WfG solution has been introduced into China's cancer treatment system. Baiyang Intelligent Technology Chairman Fu Gang, Berry Gene Chairman Gao Yang, Baiyang Intelligent Technology CMO Wang Biquan, Berry Gene CEO Zhou Daixing attended the signing ceremony.
Is the genetic sequencing gust coming? Accurate interpretation of data is key
In recent years, the gene sequencing industry has gradually matured. In 2015, the global gene sequencing market was close to 6 billion US dollars. In 2016, it was nearly 7 billion US dollars. It is estimated that the global market scale will exceed 12 billion US dollars in 2020, with a compound annual growth rate of 17% to 19%.
With the continuous development of the economy and the standardization of the sequencing market, the growth rate of China's sequencing market has become obvious. It has become the fastest growing country in the global genetic testing market. The scale of China's sequencing market is about 5.4 billion yuan in 2016. It is expected to exceed 100 in 2020. With a million yuan, the compound annual growth rate is about 20% to 25%.
The industry chain in the field of genetic technology is very simple, divided into sample collection, gene sequencing and software analysis. If large-scale application must be based on the accumulation and interpretation of massive genetic data, gene sequencing products and biological information analysis are fine genetic testing. The bottleneck and core of the market, the data interpretation is the most valuable part of the whole industry. Berry Gene is the leader in ctDNA testing for liquid biopsy in the industry. Non-invasive biopsy detection technology to detect DNA fragments of cancer cells in the blood, many medical results prove that gene sequencing can obtain more clinically executable mutation detection results, but hope to help patients obtain accurate treatment options, It is necessary to carry out rapid clinical interpretation of the test results. It takes a lot of time to rely solely on manual analysis support. Time is the most precious for patients who need fast and accurate treatment. Therefore, the birth of WfG solution is to achieve tumor. The key to accurate patient treatment for large-scale applications.
The occurrence and development of most tumors is accompanied by multiple variants of multiple genes. Nearly 500 cancer-related genes are carried by humans, and there are nearly 10 million gene mutation expression patterns. It is understood that the world's top non-artificial intelligence genes are currently sequenced. The company can identify up to 100,000 genetic variants. Manual interpretation of such complex and massive information on tumor gene mutations often takes a lot of time. At the same time, due to the uneven level of interpreters and the lack of genetic databases, it is impossible to avoid omissions in the interpretation process. Therefore, accurate treatment of tumors requires a Accurate and flawless intelligent decision assistant. The top-level cancer research institute of the University of North Carolina, the Lenberg Comprehensive Cancer Center conducted a comprehensive evaluation of WfG. Within a year, 20 patients with tumors were enrolled each week. WfG completed the week-long interpretation of the expert team in 10 minutes. Moreover, the WfG interpretation results and the expert team recommendation scheme reached 99% consistency, and also provided more targeted drug selection for more than 30% of patients.
Berry Gene CEO Zhou Daixing said: "Gene sequencing technology and accurate data analysis are essential for tumor patients to achieve precision medicine . They are mainly used in two aspects: First, tumor-targeted drug target detection and therapeutic dynamic monitoring, that is, in molecular targets. Before using the drug, it is tested whether the patient carries the drug target, improves the efficiency of the drug, and reduces the waste caused by improper use of the drug. At the same time, through continuous monitoring during and after treatment, numerous treatments such as follow-up and evaluation of efficacy The link provides accurate auxiliary basis; the second is the detection of disease susceptibility genes, identifying the genes that cause the patient's disease or whether they carry the disease-susceptible genes, and looking for the disease-targeted therapeutic drugs or other treatments for patients. The cooperation of Baiyang Intelligent Technology in WfG solutions can help patients improve the accuracy of treatment."
Watson for Genomics officially launched in China
At present, the WfG solution can support 92 types of 19 types of tumors, including but not limited to common solid tumors such as lung cancer and breast cancer, leukemia, lymphoma, myeloma, and primary tumors. Tumors, etc. At the same time, WfG has established a cooperative association with a team of 14 top cancer centers and independent medical laboratories in the United States to make clinical interpretation more standardized.
Paigang, chairman of Baiyang Intelligent Technology, said: "We are honored to have a strategic cooperation with Berry Gene. There are 4.3 million cancer patients in China every year. The increase in cancer patients has brought tremendous pressure on doctors. In recent years, The rapid development of the gene sequencing market allows us to see the urgency of individualized medical needs, so we bring the most mature WfG in the medical field to China, and its knowledge base will be updated 1-2 times a month, each time increasing. 10,000 scientific literatures and 100 clinical trials can read 200 million pages of literature in 3 seconds and can present non-structural evidence information in a structured form, avoiding the omission of clinical interpretation of variant genes, and giving tumor patients more survival. Opportunity. The cooperation between Baiyang Watson and Berry Genetics based on the Watson for Genomics solution is the first in China, and we will jointly promote the application of precision medical solutions."
As the main body of Baiyang Pharmaceutical Group's Internet application ecosystem, Baiyang Intelligent Technology is committed to science and technology to improve health. Since its strategic cooperation with IBM Watson Health on March 28 this year, it has already established 23 tertiary comprehensive medical treatments in 9 provinces and cities in China. The institution established the Watson Cancer Consultation Center. The hand-in-hand with Berry Gene is an important milestone, marking the full entry of Baiyang Watson into the genetic technology industry, which will greatly expand the application scenarios of cognitive medical solutions. Fu Gang stressed, "As the most mature cognitive computing technology, its arrival will enable the medical industry to produce a large number of hospitals and doctors who are good at applying intelligent medical tools, which will bring accurate treatment for cancer patients and the entire medical and health industry. Earth-shaking changes."
Fire Ball,Fire Fighting Ball ,Ball For Fire Fighting,Elide Fire First Aid Fire
NINGBO TOMAN IMP. & EXP. CO., LTD , https://www.tdotmfiresolution.com